Hetero Labs
- All
- News
-
Reduces Hospitalisation, Says Merck Of COVID-19 Drug, Seeks India's Ok
India's Hetero Labs said on Friday it sought emergency use nod from the local regulator for Merck's COVID-19 drug molnupiravir, after interim data from a late-stage trial showed it helped reduce hospitalisations and speed up recovery in mild cases.
-
Hetero Labs Wins Approval To Sell COVID-19 Drug Favipiravir
The drug, priced at Rs 59 per tablet, is approved to treat mild to moderate COVID-19
-
Hyderabad-Based Hetero Prices Generic COVID-19 Drug At Rs 5,400 Per Vial
Hyderabad-based Hetero Labs Ltd has priced its generic version of remdesivir, Gilead's experimental COVID-19 drug, at Rs 5,400 ($71) per 100-milligram vial, the drug maker said on Wednesday, as it prepares to ship them to hospitals in the country.
-
Lupin, 5 Other Pharma Firms Ink Licensing Pact With Medicines Patent Pool
Indian pharma firms Aurobindo, Emcure, Hetero Labs, Laurus Labs, Lupin and Zydus Cadila are among the seven drug makers which have signed licensing pact with UN-backed Medicines Patent Pool (MPP) for producing HIV and hepatitis C drugs.
-
Dr Reddy's Labs Gains on Plans to Launch Hepatitis C Drug
Hetero had signed a non-exclusive agreement with Gilead Sciences to manufacture and sell its Hepatitis medicines.
-
Reduces Hospitalisation, Says Merck Of COVID-19 Drug, Seeks India's Ok
India's Hetero Labs said on Friday it sought emergency use nod from the local regulator for Merck's COVID-19 drug molnupiravir, after interim data from a late-stage trial showed it helped reduce hospitalisations and speed up recovery in mild cases.
-
Hetero Labs Wins Approval To Sell COVID-19 Drug Favipiravir
The drug, priced at Rs 59 per tablet, is approved to treat mild to moderate COVID-19
-
Hyderabad-Based Hetero Prices Generic COVID-19 Drug At Rs 5,400 Per Vial
Hyderabad-based Hetero Labs Ltd has priced its generic version of remdesivir, Gilead's experimental COVID-19 drug, at Rs 5,400 ($71) per 100-milligram vial, the drug maker said on Wednesday, as it prepares to ship them to hospitals in the country.
-
Lupin, 5 Other Pharma Firms Ink Licensing Pact With Medicines Patent Pool
Indian pharma firms Aurobindo, Emcure, Hetero Labs, Laurus Labs, Lupin and Zydus Cadila are among the seven drug makers which have signed licensing pact with UN-backed Medicines Patent Pool (MPP) for producing HIV and hepatitis C drugs.
-
Dr Reddy's Labs Gains on Plans to Launch Hepatitis C Drug
Hetero had signed a non-exclusive agreement with Gilead Sciences to manufacture and sell its Hepatitis medicines.
